Quick Answer
Honvan — Fosfestrol Tetrasodium 120 mg (Asta Medica). Diethylstilbestrol diphosphate — high-dose estrogen for advanced metastatic prostate cancer. Largely replaced by LHRH agonists; remains in resource-limited or palliative settings.
Αυτό που λαμβάνετε με την MedsBase:
- WHO-GMP certified manufacturer
- Discreet plain-envelope packaging
- Παγκόσμια αποστολή
- Rated by 1,400+ customers (read reviews)
📦 Reshipment Assurance: if your order has not arrived 20 business days after dispatch, we reship it at no extra cost. Read the policy.
Γιατί να παραγγείλετε από τη MedsBase
Honvan ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
Fosfestrol carries substantial cardiovascular risk — DVT, PE, MI, stroke, fluid retention. Use only when modern alternatives (LHRH agonists, abiraterone, enzalutamide) are unavailable or unsuitable. Mandatory thromboprophylaxis discussion with cardiology.
Συχνές Ερωτήσεις
When is this used?
Diethylstilbestrol diphosphate — high-dose estrogen for advanced metastatic prostate cancer. Largely replaced by LHRH agonists; remains in resource-limited or palliative settings.
Side effects to watch?
Hot flushes, gynaecomastia, fatigue, sexual dysfunction (anti-androgen class effect). Drug-specific monitoring as outlined in the safety boxes above.
Drug interactions?
Vary by molecule — abiraterone is CYP3A4 substrate; bicalutamide is CYP3A4 substrate. Always disclose all medications. Strong CYP3A4 inhibitors/inducers significantly affect levels.
When should it be stopped?
On disease progression, intolerable toxicity, or successful response with planned treatment break. Always specialist-decided — abrupt cessation can result in transient PSA rise (withdrawal response) which is generally not concerning.
PSA monitoring?
PSA every 1-3 months while on therapy. Rising PSA on castration suggests castration-resistance — may need switch to second-line agents (abiraterone, enzalutamide, docetaxel).
Combined androgen blockade?
LHRH agonist (goserelin, leuprolide) + bicalutamide is a common combination. Maximal androgen blockade has modest survival benefit over LHRH alone.
Bone health?
Long-term androgen deprivation accelerates bone loss. Add a bisphosphonate (zoledronic acid) or denosumab in osteopenia/osteoporosis. Calcium and vitamin D supplementation.
Pregnancy?
Anti-androgens are teratogenic — partners must use effective contraception during therapy. Most relevant for younger men with localised disease.
What if I miss a dose?
Take when you remember if same day; otherwise skip. Specialist may have specific guidance for missed doses depending on regimen.
Cardiovascular monitoring?
Mandatory for fosfestrol; advised for abiraterone (BP, fluid retention, electrolytes); routine for bicalutamide (occasional CV review).
Other Cancer & Anti-Androgen Therapy
- Calutide — bicalutamide 50 mg — alternative anti-androgen brand
- Xbira — abiraterone 250 mg — CYP17 inhibitor for mCRPC
- Honvan — fosfestrol 120 mg — diethylstilbestrol diphosphate
- Estramustine — estramustine phosphate — alkylator for hormone-refractory disease
- Zoldria — zoledronic acid IV for bone metastases

























Κριτικές
Δεν υπάρχουν ακόμη κριτικές